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Reduced angiotensin receptors and pressor responses in
hypotensive hemodialysis patients
THOMAS J. MOORE, J. MICHAEL LAZARUS, and RAYMOND M. HAKIM,1 with the technical
assistance of JUDY NEWELL and AMELIA NUNN
Endocrine-Hypertension Division and Nephrology Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical
School, Boston, Massachusetts, USA
Reduced angiotensin receptors and pressor responses in hypotensive
hemodlalysis patients. A sub-set of patients on chronic hemodialysis
develop sustained hypotension (systolic pressure < 100 mm Hg). To
determine whether this hypotension could be due to altered production
of, or sensitivity to angiotensin II (All), we measured plasma renin
(PRA), All, and aldosterone in nine hypotensive and nine normotensive
dialysis patients; we also assessed their sensitivity to infused All and
studied All binding to their platelets as an indicator of All receptors on
vascular smooth muscle. All studies were performed just before dialysis
when subjects were relatively volume-expanded. Hypotensives had
higher PRA (5.7 2.4 vs. 2.1 0.8 ng AI/ml/hr, P < 0.05), All (56
15 vs. 31 3 pg/mI), and aldosterone (91 35 vs. 21 7 ng/dl, P <
0.05) than did normotensives. During All infusion at 1, 3, 10, and 30
ng/kg/min for 15 minutes each, hypotensives displayed a significantly
blunted pressor effect across the range of All doses. In parallel with
this, hypotensives showed reduced All receptors on their platelets
compared to normotensives (0.8 0.4 vs. 3.6 1.0% 1251-AII specifi-
cally bound; P < 0.03). Binding analysis revealed a single affinity state
for the All receptors which was similar in both groups (Kd = 3.2 1.1
for hypotensives vs. 3.8 0.7 X 10b0 M for normotensives). The two
groups had similar levels of plasma catecholamines, similar slowing of
heart rate during All infusion and no postural hypotension, indicating
intact sympathetic nervous system pathways. Thus, hypotensive dial-
ysis patients display both a reduced pressor response to infused All and
reduced All receptors on their platelets. This defective All responsive-
ness may contribute to the hypotension in these patients.
Hypertension is a common manifestation of chronic renal
failure and is present in more than 90% of such patients. It often
persists after initiation of dialysis. A gradual decrease in the
estimated dry weight (EDW) of patients on dialysis and institu-
tion of antihypertensive medications is often needed to control
BP to acceptable range.
Less well known and more difficult to treat, however, are a
subset of dialysis patients with chronic hypotension, defined as
systolic BP < 100 mm Hg predialysis which often declines
further during dialysis. A systematic investigation of cardiac,
pericardial, volume factors or autonomic neuropathy is often
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non-contributory in evaluating the cause of their hypotension,
and the etiology of this hypotension remains unclear. This
group has been estimated to comprise approximately 10% of the
dialysis population and may be more prevalent in long-term
hemodialysis patients. Although their proportion is small, these
patients require a substantial amount of physician and nursing
time during and after dialysis to control hypotensive symptoms.
Angiotensin II (All) is an important regulator of blood
pressure, and All's effect on blood pressure is accentuated by
several factors including a high dietary salt intake and expanded
intravascular volume [1, 2]. Results of animal studies suggest
that these conditions enhance vascular sensitivity to All by
suppressing the plasma All level and promoting up-regulation
of the number of vascular smooth muscle All receptors [3, 4].
More recently, studies by Moore et alEs, 6] have demonstrated
that human platelets possess All receptors which are regulated
by sodium intake in parallel with the regulation of All receptors
in animal smooth muscle and renal glomeruli [4, 7]. To deter-
mine whether hemodialysis hypotension could be related to
diminished responsiveness to All, we investigated the blood
pressure response to infused All as well as the characteristics
of the platelet All receptors in two populations of non-diabetic
chronic dialysis patients: one group who were chronically
hypotensive and another group who were normotensive.
Methods
Subjects
Hypotensive group. Nine patients with systolic BP < 100 mm
Hg pre-dialysis for at least the previous three months were
asked to participate. The clinical characteristics of the hypoten-
sive group are shown in the Table 1. Mean time on dialysis for
this group was 10.5 years. Mean arterial pressure (MAP =
diastolic + 1/3 pulse pressure) for this group was 61.0 2.3 mm
Hg (mean SEM). Two of these patients had undergone
bilateral nephrectomy in the distant past. None of these patients
were diabetic or on anti-hypertensive or antianginal medica-
tions.
Previous investigation of the causes of hypotension in these
patients was unrewarding. None had evidence of cardiac dis-
ease (as documented by EKG, echocardiography and ausculta-
tion and, in 3 of the 6, by MUGA scan), and none had previous
history of pencardial disease, myocardial infarct, or echocar-
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Table 1. Patient characteristics, Hypotensive Group
Years on Kidneys native! BP syst/
Initial Age Sex dialysis Diagnosis transplant diast MAP
AG 30 F 8 Goodpasture 2/0 72/48 56
CC 43 F 7 Chronic GN 0/1 72/48 56
ST 30 M 16 FSG 2/0 84/56 15
DE 73 F 4 Nephrosclerosis 2/0 85/50 62
EM 65 M 15 PCKD 2/0 92/50 64
AN 69 F 5 Interstitial 2/0 99/56 70
MC 35 M 15 Alport's 2/0 89/56 67
JM 36 F 9 Cong. renal hypoplasia 2/0 79/52 61
CR 50 F 16
Table 2.
Goodpasture 0/0
Patient characteristics, Normotensive Group
63/40 48
Initial Age Sex
Years on
dialysis
Kidney native!
Diagnosis transplant
BP syst/
diast MAP
EMc 56 F 10 PCKD 2/0 157/78 104
VR 70 F 4 Obstructive uropathy 2/0 154/84 107
JB 65 M 5 Obstructive uropathy 2/0 113/62 79
MMc 73 F 3 Nephrosclerosis 2/0 108/68 81
WT 54 M 14 Pylonephritis 2/0 115/78 90
SC 60 M 6 Nephrosclerosis 2/0 114/70 84
1W 80 F 9 Nephrosclerosis 2/0 154/82 106
FS 55 F 4 Hypertension 2/0 133/89 104
DG 80 F 4 Nephrosclerosis 2/0 126/63 84
diographic features of restrictive cardiac disease. None of these
patients had any evidence of systemic infiltrative disease (amy-
bid, sarcoid) but one (C.C.) had evidence of iron overload as
documented by a ferritin level of 7,100 ng/ml. Attempts at
increasing BP by increasing estimated dry weight (EDW) often
resulted in only minimal or no increase in BP but a marked
increase in signs and symptoms of fluid overload, including
cephalization of pulmonary vasculature, development of Kerley
B lines on chest x-ray and a marked increase in shortness of
breath at rest and on exertion. Thus, these patients' EDW was
considered to be at the upper range of optimum and they were
considered volume replete.
Normotensive group. Nine chronic dialysis patients with
diastolic BP between 80 and 90 mm Hg and mean arterial BP of
93.3 3.7 mm Hg and not on any anti-hypertensive medica-
tions were asked to serve as controls. Mean time on dialysis for
this group was 6.5 years. Other relevant characteristics of these
patients are shown in Table 2. Again, none of these patients had
any evidence of cardiac or pericardial disease and none had
evidence of cardiac or pericardial disease and none had evi-
dence for other systemic diseases such as diabetes, amyboidosis
or hemochromatosis. All nine of these patients underwent
hormonal and platelet All receptor analysis, but only five
participated in the All infusion protocol.
Study design
All studies were done pre-dialysis, on a day following a
72-hour hiatus without dialysis. The average interdialytic
weight gain for the hypotensive group between these two
treatments was 3.2 0.4 kg and 3.4 0.3 kg for the normoten-
sive group. This difference was not statistically significant.
Patients were allowed to remain sitting for 10 minutes before
initiation of the study. Postural (sitting and standing) BP were
also taken prior to initiation. None of these patients exhibited a
postural change in systolic blood pressure greater than 9 mm Hg
prior to initiation of the study. Blood was obtained from the
usual hemodialysis access for renin (PRA), All, aldosterone,
catecholamines (epinephrine, norepinephnne and dopamine),
and potassium levels. All blood samples were immediately
centrifuged at 4°C and plasma was separated and frozen until
the time of the assay. Samples for measurement of PRA and All
levels were drawn into EDTA as the anticoagulant, and plasma
then stored in a tube containing difluorophosphate (DFP).
Samples for aldosterone were drawn in a heparinized tube while
samples for catecholamines were drawn in a tube containing
EGTA and reduced glutathione.
Following an observation period of 15 to 20 minutes, Angio-
tensin il-amide (HypertensinR, Ciba-Geigy Corp., Pharmaceu-
tical Division, Summit, New Jersey, USA) was infused at
successive doses of 1, 3, 10, and 30 nglkglmin for 15 minutes
each using an electronic infusion pump (Harvard Apparatus
Co., Millis, Massachusetts, USA). Blood pressure (systolic,
diastolic, and MAP) as well as heart rate were measured and
recorded every two minutes using an indirect-recording, oscil-
lometric sphygmomanometer (DinamapR). All infusion rate
was changed at the end of each observation period. After
initiating or increasing to a new All dose, the first blood
pressure reading was discarded; all subsequent readings were
averaged and taken as the blood pressure response to each
dose.
Platelet All receptor assay
We have previously reported the methods used for preparing
the platelets and assessing All binding [5]. In brief, platelets
were isolated by centnfugation of buffy coats of whole blood
sample pre-dialysis and before any infusion of All. These
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platelets were then resuspended in medium 199 (Grand Island
Biological Co., Grand Island, New York, USA) containing 3.6
m potassium, 0.5% BSA, and 5 mrvi EDTA and diisopropyl-
fluorophosphate. Aliquots of this platelet suspension (contain-
ing 2.8 x 108 platelets/400 pl) were then incubated with tracer
amounts (30 pM) of '251-AII (1500 to 1800 Ci/microgram; New
England Nuclear, Cambridge, Massachusetts, USA). Varying
concentrations of unlabeled Al! were added (0.05 to 10 nM)and
incubated for 90 minutes. To separate bound from free hor-
mone, duplicate 200-z1 aliquots of these incubations were
microcentrifuged through dibutylphthalate oil, as described by
Gambhir, Archer and Bradley [8]. The platelet pellet was
counted as bound and the supernate as free hormone in a
Packard gamma-counter (Packard Instrument Co., Inc., Down-
ers Grove, Illinois, USA). Bound and free '251-AII counts were
calculated after centrifugation. Nonspecific binding was defined
as binding in the presence of 1 pM unlabelled All. Nonspecific
binding of tracer amounts of '251-AII (30 pM) represented less
than 1% of the added tracer and 10 to 30% of the total binding.
All binding results presented here have been corrected for
nonspecific binding.
Binding data were analyzed with the curve-fitting program,
LIGAND [9]. In all cases, analysis suggested a single affinity
state for the receptor. In five of the nine hypotensive patients
and two of nine normotensives, either the platelet yield (N = 1)
or the specific binding (N = 6) was so low that a full binding
curve could not be constructed. Binding data are therefore
presented as the percentage of '251-AII (30 pM) specifically
bound to platelets (Bs). In the patients where the amount of
binding permitted construction of a full binding curve, binding
affinity was similar in both normotensive and hypotensive
groups. Thus, Bs serves as an index of binding capacity.
Assay procedures
Plasma All and PRA were measured by radioimmunoassay
as previously reported [10]. Our All antiserum shows 0.03%
cross-reactivity with angiotensin I but recognizes All and
des-Asp Ang II (angiotensin III) equally. Aldosterone from
plasma samples was assayed by the Coat-a-count' assay kit
(Diagnostic Products, Los Angeles, California, USA). Aldoste-
rone levels using this assay correspond well with levels using
our previous assay. Its intra-assay and interassay coefficients of
variation are less than 8% and less than 10%, respectively, and
the lower limit of detectability is 1.6 ng/dl.
Catecholamines were determined by a modification of the
method of Peuler and Johnson [11]. In brief, heparinized plasma
was made 5 m in an EGTAIGSH solution; 100 .d aliquots were
assayed internal standard. Sterile water was prepared in
plasma/urine catecholamine tubes and used as assay blank.
Methyl-labelled 3H-S-adenosyl methionine (3H-SAM) was used
to 3-0-methylate the catecholamines in 100 tl plasma or 50 p1
urine, the resulting products being 3H-normetanephrine, 3H-
metanephrine, and 3H3-methoxytyramine. These were sepa-
rated by a thin layer chromatography after a periodate reaction,
and the radioactivity counted in a liquid scintillation counter.
Catechol-O-methyl transferase, (COMT), prepared from rat
livers, was used to catalyze the reaction. Benzylhydroxylamine
hydrochloride was used to inhibit the formation of dopamine
from plasma DOPA due to the DOPA decarboxylase activity
present in the COMT preparation. EGTA was added directly to
the plasma sample to prevent the inhibitory influence of plasma
calcium.
To permit comparison of these dialysis subjects' hormone
levels with normal levels from our laboratory, we have indi-
cated the ranges for supine, sodium-replete normal subjects:
PRA 0.5 to 3.0 ng AI/ml/hr; All <20 to 30 pg/mI; aldosterone
1 to 10 ngldl; norepinephrine 100 to 340 pg/ml; epinephrine 20 to
70 pg/ml; dopamine < 60 pg/mI. Our subjects were semi-
recumbent in dialysis chairs when their blood samples were
drawn.
Statistical analysis
Data are presented as mean standard error of the mean.
Data analysis was performed with the support of the CLINFO
data analysis system of the Brigham and Women's Hospital
Clinical Research Center. For comparison between hypoten-
sive and normotensive groups, the unpaired f-test was used for
normally distributed data and the Fisher exact test (FET) was
used when data were not normally distributed. The null hypoth-
esis was rejected when P < 0.05.
Results
In addition to their significantly lower blood pressure, the
hypotensive subjects were younger than the normotensive
subjects (48 6 vs. 66 3 years; P < 0.02). There was no
obvious difference in the types of underlying renal diseases in
the two groups (Tables 1 and 2). Hypotensive patients had
required dialysis longer than normotensives (10.5 vs. 6.5 years),
but the difference was not significant (0.1 > P > 0.05).
Hypotensive subjects displayed higher levels of plasma renin,
All and aldosterone than did normotensive dialysis subjects
(Fig. 1). Renin levels were more than twofold higher in the
hypotensives than normotensives (5.7 2.4 vs. 2.1 0.8 ng
AI/ml/hr; P < 0.05) and aldosterone was similarly elevated in
the hypotensive group (91 35 vs. 21 7 ng/dl, respectively;
P < 0.05). The difference in All levels (56 15 vs. 31 3 pg/mi)
was less marked (0.1 > P > 0.05).
Plasma catecholamine levels were elevated above the normal
range in both dialysis groups and tended to be slightly, but not
significantly, lower in the hypotensive subjects (Table 3). Rest-
ing heart rate was greater in hypotensive than normotensive
subjects (85 6 vs. 74 8; P = 0.06, FET).
The pressor response to infused All was blunted in hypoten-
sive subjects. This was most evident in the systolic and mean
arterial pressure responses. The difference between the groups
at any single dose was not significant, but, when the responses
at all four doses were analyzed together, hypotensives were
significantly less responsive than the normotensives (P < 0.05,
FET; Fig. 2). Both groups displayed decreases in heart rate
during All infusion, confirming an intact baroreceptor pathway
(Fig. 3).
Angiotensin II binding to platelets was significantly reduced
in hypotensive subjects, consistent with their reduced pressor
response to infused All. In the subjects where analysis of All
binding over a range of All concentrations was possible (N = 4
hypotensive and 7 normotensives), binding affinity was similar
in the two groups (Kd 3.2 1.1 X M in hypotensives vs.
3.8 0.7 x 10— 10 M in normotensives), but receptor density
was less in hypotensives (8.6 4.2 vs. 16.5 4.2 fmolIlO9
platelets, respectively). In the remaining hypotensive subjects,
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Fig. 1. Plasma renin activity, All, and aidosterone levels in hemodi-
alysis subjects just prior to dialysis. Subjects with chronic hypotension
showed an activated R-A-A axis, with significantly higher PRA and
aldosterone (*P < 0.05). Symbols are: () hypotensives; ()normoten-
sives.
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Table 3. Plasma catecholamines hemodialysis subjects
Norepinephrine Epinephrine Dopamine
pg/mi
Hypotensives 493 167 57 12 82 18
Normotensives 521 78 86 18 140 52
1 3 10 30
All dose, ng/kg/min
Fig. 2. Systolic (A) and mean arterial pressure (B) response to graded
doses of infused All. Hypotensive subjects had a significantly blunted
pressor response (P < 0.05with both measurements). Symbols are: (0)
normotensives; (•) hypotensives.
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Fig. 3. Heart rate response during All infusion. Both patient groups
showed a decline in heart rate, with no significant intergroup differ-
ences. Symbols are (0) normotensives; (•) hypotensives.
basal (that is, pre-All infusion) mean arterial pressure (r = 0.5;
P < 0.05). There was no correlation between any of the plasma
hormone levels and either resting blood pressure or the pressor
response to All. Finally, despite the tendency that hypotensive
subjects had been on hemodialysis longer than normotensives,
platelet All binding was so reduced that full analysis of binding
curves was not possible. However, since receptor affinity
(outlined above) was identical in the hypotensive and nor-
motensive subjects and, where possible, analysis indicated only
a single affinity for the receptor, we have used the percent
'251A11 (30 pM) specifically bound to platelets as an indirect
measurement of platelet All binding capacity. When analyzed
in this way, hypotensive subjects displayed less than 25%of the
binding seen in normotensive subjects (0.8 0.4 vs. 3.6
1.0%; P < 0.03; Fig. 4).
When both normotensives and hypotensives were pooled
together, there was no significant correlation between platelet
All binding and the blood pressure change during AL! infusion,
but a significant correlation did exist between All binding and
1 3 10 30
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there was no correlation between length of time on dialysis and
either the blood pressure responsiveness to All or the level of
platelet All binding (Fig. 5).
Discussion
Our study demonstrates that hypotensive dialysis patients are
resistant to the vasoconstrictor effect of infused All. This
finding was associated with both elevated plasma renin and All
levels as well as with significantly-reduced platelet Al! recep-
tors. We have shown that platelet A!! binding is very reproduc-
ible in any given subject [6]. Since our original description,
others have identically confirmed the characteristics of the
platelet All receptor [12, 13]. Previous studies from our labo-
ratory [5, 6] also show that platelet All receptors resemble
receptors on vascular smooth muscle [4] both in affinity and in
their regulation by dietary sodium intake. Our results therefore
suggest that the reduced pressor response to ambient and
infused All in these chronically hypotensive patients is due to
reduced A!! receptors in their vascular bed.
Previous investigators have examined possible abnormalities
in the autonomic nervous system as the etiology of this chronic
hypotension [14—16]. However, in a systematic study by Nies,
Robertson and Stone [14] indices of peripheral autonomic
nervous function were similar in normotensive and chronic
hypotensive hemodialysis patients (such as, the response to
valsalva maneuver, cold pressor test, plasma catecholamine
levels, responses to norepinephnne and tyramine infusions). In
another study, lmai et al [15] studied the cardiac-hemodynamic
aspects of similar subsets of dialysis patients and found no
difference in cardiac index, no correlation between mean arte-
rial pressure and cardiac index, and no difference in plasma
volume between the hypotensive and normotensive hemodial-
ysis patients. However, they did find significantly lower total
peripheral resistance in the hypotensive patients compared to
normotensive controls.
Although we did not formally investigate the integrity of the
sympathetic nervous system in either groups of patients, none
of the patients in this study had any significant postural changes
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in blood pressure, and the slope of the heart rate response to
elevation of blood pressure during Al! infusion was identical in
both patient subsets, indicating intact baroreceptor function.
Plasma catecholamine levels were elevated in our subjects
(compared to levels in the normal population), consistent with
the elevation previously reported in dialysis patients [17]. The
levels were similar, however, in both our normotensive and
hypotensive groups.
More recently, Daul et al [16] found that hypotensive dialysis
patients have higher plasma catecholamine levels, a blunted
pressor response to phenylephrine, and reduced alpha2 recep-
tors on their platelets. In their subjects, these defects increased
in parallel with the duration of dialysis treatment. Our findings
with angiotensin, in part, resemble Daul's findings with cate-
cholamines: reduced pressor response to infused A!! and re-
duced Al! receptors on platelets in the hypotensive group. We
found no correlation, however, between these defects and the
duration of dialysis (Fig. 5).
Other investigators have also noted a tendency to a blunted
pressor effect of A!! in hypotensive dialysis patients. Sorensen
et al [18] found that hypotensives required a greater A!!
infusion rate to achieve a given blood pressure increment than
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Fig. 4. Angiotensin II binding to platelets. Binding is displayed as the
percentage of '251-AlI (30 pM) specifically bound to platelets. Hypoten-
sive subjects displayed significantly less binding than normotensives (P
<0.03).
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pressor effects of infused A!! (A) and platelet A!! binding (B). There is
no significant correlation in either case. Symbols are: (0) normoten-
sives; (•) hypotensives.
Time, years on hemodialysis
0
y = —0.23x + 4.12
r = —0.36; p = N.S.0
00 • 0
0
0_ • I
Moore et a!: Angiotensin in hypotensive HD patients 701
did normotensive dialysis subjects, although the difference
between infusion rates in the two groups was not significant.
Tajiri et al [19] found that hypotensives had blunted pressor
responses to All but reported the response to only a single dose
of All. Our results expand and clarify these earlier reports in
two important ways: by demonstrating a blunted pressor effect
of All across a range of All doses, and by showing down-
regulation of platelet All receptors in the hypotensive group.
In summary, our results suggest that reduced sensitivity to
angiotensin II may play a role in the hypotension which some
hemodialysis patients exhibit. Our results do not resolve where
the primary defect lies. It is possible that some dialysis patients
develop reduced responsiveness to vasoconstrictors as a pri-
mary event. Secondary to this, plasma renin and angiotensin II
levels increase as a compensatory measure and lead to reduced
angiotensin receptor density, further contributing to the re-
duced vascular sensitivity. Alternatively, the primary defect
may lie at the level of the angiotensin II receptor itself, resulting
in reduced sensitivity to angiotensin II, hypotension, and sec-
ondary increases in renin and angiotensin levels. Further stud-
ies will be needed to determine where the primary defect lies in
these subjects.
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